United StatesHealth

Oscar Health (NYSE:OSCR) reported a complex finish to 2025 on Tuesday, February 10, 2026, revealing a widening quarterly loss even as it achieved a historic membership milestone.

Organigram Global (NASDAQ:OGI) reported a dominant start to its fiscal 2026 on Tuesday, posting a 49% year-over-year surge in net revenue to $63.5 million.

Koninklijke Philips (NYSE:PHG) reported a return to profitability in its fourth quarter, bolstered by a 7% rise in comparable sales and the successful rollout of AI-driven medical imaging systems.

AstraZeneca (NASDAQ:AZN) reported fourth-quarter and full-year 2025 results on Tuesday that failed to meet Wall Street’s expectations, as a surge in operating costs for its expanding drug pipeline dampened the impact of double-digit sales growth in its oncology division.

Biofrontera (NASDAQ:BFRI) has achieved a significant clinical milestone, announcing that its Phase 3 trial of Ameluz® photodynamic therapy (PDT) met its primary endpoint for the treatment of mild-to-moderate actinic keratoses (AK) located on the extremities, neck, and trunk.

Telehealth provider Hims & Hers Health (NYSE:HIMS) transitioned from a marketing high to a legal defense on February 9, 2026, as Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) filed a lawsuit alleging patent infringement and deceptive marketing

MannKind (NASDAQ:MNKD) announced a major clinical milestone Monday, enrolling the first patient in its INHALE-1ST study just as it prepares for a transformative FDA decision that could introduce the first needle-free insulin for children in over a century.

TransMedics Group (NASDAQ:TMDX) reached a pivotal regulatory milestone Monday, receiving full and unconditional approval from the FDA to launch its next-generation OCS ENHANCE Heart trial.

Indianapolis-based Eli Lilly and Company (NYSE:LLY) announced on February 9, 2026, that it has agreed to acquire Orna Therapeutics, a biotechnology company pioneering circular RNA and novel lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies.

Anavex Life Sciences (NASDAQ:AVXL) reported a narrowed net loss and a robust cash position for its fiscal first quarter, providing the clinical-stage biotech with a three-year financial cushion as it contests a regulatory setback in Europe and prepares for pivotal U.S. filings.

Edgewell Personal Care (NYSE:EPC) today reported first-quarter results that modestly exceeded internal expectations, as the company finalized a major strategic pivot by divesting its Feminine Care business to Essity for $340 million.

Novo Nordisk (NYSE:NVO) shares rebounded in Frankfurt on Monday after telehealth provider Hims & Hers Health (NYSE:HIMS) abruptly scrapped the launch of a low-cost, compounded weight-loss pill following an aggressive regulatory warning from the U.S. Food and Drug Administration.